A European project leads to a new diagnosis of the Ebola feverFebruary 26, 2002Research teams involved in a European project have developed and tested in epidemic conditions a new diagnosis technique of infections by the Ebola virus. This has been achieved while a new haemorrhagic Ebola fever epidemic is striking Gabon since December. For Research Commissioner Philippe Busquin, "this advance shows the interest of an international and multi-field co-operation between European and African teams on important subjects for human health whose impact goes beyond the borders of a country or even a continent. In this context, it is crucial for all to better understand, better detect and better treat illnesses such as the Ebola fever." The Ebola virus has been known since 1976 in Africa where it caused mortal human epidemics in the Democratic Republic of Congo (DRC) and in Sudan. After a long silence, the virus reappeared in 1994 on six different sites in Africa: Côte d`Ivoire in 1994, DRC in 1995, Uganda in 1999, and Gabon in 1994, 1995, and 1996. For the fourth time, an haemorrhagic Ebola fever epidemic occurred in Gabon at the end of 2001, in the region of Ogooué Ivindo (Mékambo). The haemorrhagic Ebola fever was diagnosed by the International Medical Research Centre of Franceville (CIRMF) on 8 December. A secondary epidemic then appeared in a village of Congo Brazzaville located a few kilometres from the border as a result of patients arriving from Gabon. The origin of contamination seems to be a contact with a large monkey (chimpanzee or gorilla) infected by the Ebola virus. Moreover, an epizootic is also affecting large monkeys, as numerous gorillas and chimpanzees - likely to infected by the Ebola virus - died in the region. To date, the epidemic is still not over and there are currently 42 confirmed cases, including 34 deaths, and several non-confirmed cases are still hospitalised. Numerous persons having been in liaison with patients are also under monitoring. In this context, scientists from the Mérieux-Pasteur Research Centre in Lyon (CRMPL, Association Fondation Mérieux and Institut Pasteur) have been able to test in CIRMF laboratories (Gabon) a new diagnosis technique based on the detection of viral genomes (see annex). In the current epidemic context, the new and simplified test seems very satisfactory and shows sensitivity similar to the RT-PCR standard technique, which would allow detecting the infection among patients at an early stage of the symptoms. The international co-operation supported by the European Union has proven successful to provide a solution in an epidemic situation and to contribute to the technological development of poor countries. In fact, this achievement has been made possible through combining the know-how of several laboratories working on polymer chemistry, colloidal physico-chemistry, viral haemorrhagic fevers and field workers of an endemic area (see annex). The impact for public health is obvious as it will allow identifying ill persons and taking preventive measures to avoid secondary infections. This rapid, precise and robust identification technique of virus in blood will make it possible to apprehend better the epidemic in the blossoming phase and to implement a suitable therapeutics when it will be available. European Commission, Research Directorate |
|||||||||||||||||||||
| Related Ebola Current Events and Ebola News Articles 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. Outfoxing pox: Developing a new class of vaccine candidates In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox. World will miss 2010 target to stem biodiversity loss, experts say The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science. Scientists block Ebola infection in cell-culture experiments Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells. OHSU scientists partner with others to form center aimed at combating infectious diseases Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health. Drug blocks 2 of world's deadliest emerging viruses Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology. Penn Study Identifies How Ebola Virus Avoids the Immune System Researchers at the University of Pennsylvania School of Medicine have likely found one reason why the Ebola virus is such a powerful, deadly, and effective virus. Using a cell culture model for Ebola virus infection, they have discovered that the virus disables a cellular protein called tetherin that normally can block the spread of virus from cell to cell. Iowa State University researchers discover structure of key Ebola protein Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. More Ebola Current Events and Ebola News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||